Panolos Bioscience specializes in the development of structure-based multi-specific biologics, focusing on innovative therapies for patients suffering from difficult-to-treat diseases. Their approach emphasizes the creation of multi-specific therapeutics that can target multiple pathways simultaneously, thereby enhancing therapeutic efficacy and minimizing side effects. The company is dedicated to advancing drug development through collaborative models, aiming to improve patient outcomes and quality of life.

One of their key products, PB203, is a multi-specific immune-oncology drug that targets PD-L1 expressing tumors. It operates through a novel mechanism that simultaneously inhibits PD-L1, VEGF, and PlGF signaling, effectively increasing drug concentration within the tumor microenvironment. This mechanism not only controls T cell exhaustion induced by PD-L1 but also restricts abnormal angiogenesis and fibroblast activation, ultimately leading to tumor regression. Additionally, Panolos has developed the α ART™ platform, which allows for the creation of multi-specific therapeutics with enhanced functionality and reduced production costs, further expanding their therapeutic applications to include autoimmune diseases.

South Korea

Panolos Biosciences is at the forefront of structure-based protein design, ceaselessly pushing the limits of multi-specific drug development. We are dedicated to the creation of anti-angiogenic therapies for the treatment of cancer, autoimmune, and rare diseases. Our unique patented technology, "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific)", employs a VEGF receptor backbone to develop mono or multi-specific antibody therapeutics, amplifying their potency.

Panolos Bioscience

Company Details